Skip to main content
Caplight Logo









Remedly

Remedly

Private
Oakland, CaliforniaHealthcare & Life Scienceshttps://www.remedly.com/

Last Round

Series A

Mar 9, 2021

Est. Valuation

$11.93M

Total Funding Raised

$6.24M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Remedly is a healthcare software company that provides an all-in-one, cloud-based platform combining Electronic Health Records (EHR), Revenue Cycle Management (RCM), and practice management solutions for specialty medical practices.

Sector

Healthcare & Life Sciences

Verticals

EHR & EMR, Vertical SaaS, Patient Engagement, Revenue Cycle, Fashion & Beauty

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

practice management softwareelectronic health recordEHRmedical spa softwarerevenue cycle managementRCMplastic surgery softwarepatient portalvertical SaaSaesthetic medical softwareinventory managementEMRmedspa CRMmedical billing softwarepatient engagement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Remedly Comparables

Compare Remedly with similar companies based on industry and business-model similarity.

Remedly comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Prospyr Medical, Inc.
91%
Symplast
91%
Aesthetic Record
90%

Remedly Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 9, 2021
Series AOct 20, 2020
SeedMar 10, 2017
AcceleratorMar 9, 2017

Key People

Founding team and executive leadership

Alexander Alishoev

CTO

Executive Team

Remedly Investors

Notable investors and investment history

Remedly investors
InvestorRounds
StartXSeed, Accelerator
FCA Venture PartnersSeries A
Ulu VenturesSeries A
LEO Innovation LabSeries A, Seed, Accelerator
HealthboxAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 16, 2026

    Grew 25% QoQ, from 12 to 15 employees.

  • Jun 23, 2026

    Grew 25% QoQ, from 12 to 15 employees.

Remedly Filings

Explore SEC and related filing metadata, where available.

Remedly filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Remedly's valuation, stock price, and market status.

Is Remedly a public or private company?

Remedly is a private company.

What is the current stock price of Remedly?

Remedly is a private company with no public stock price. No recent secondary market data is available.

How much is Remedly worth (valuation)?

Valuation information for Remedly is not publicly available.

Can I buy Remedly stock?

Remedly shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Remedly's last funding round?

Remedly's most recent funding round was Series A on February 26, 2021.

Who are the main investors in Remedly?

Key investors in Remedly include LEO Innovation Lab.

Will Remedly IPO soon?

No public IPO plans have been announced for Remedly.

How can I track Remedly secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remedly's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOakland, California
Employee Range15
Year Founded2013
Last FundingMar 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?